Clinical trialNCT00740610CompletedPhase 2Interventional

Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)

SponsorGilead SciencesEnrollment124Nonalcoholic Steatohepatitis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The overall purpose of this study is to examine the safety, tolerability, pharmacokinetics (how the body processes a drug), and activity of GS-9450 in preventing liver damage due to scarring, or fibrosis, caused by Non-Alcoholic Steatohepatitis (also known as NASH).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Elsa Mondou, MD
Gilead Sciences
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

33 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

France

Facility name not stated
Paris, France
Facility name not stated
Vandœuvre-lès-Nancy, France

United States

Facility name not stated
Tucson, Arizona, United States
Facility name not stated
Fresno, California, United States
Facility name not stated
Fullerton, California, United States
Facility name not stated
San Diego, California, United States
Facility name not stated
San Mateo, California, United States
Facility name not stated
Lakewood, Colorado, United States
Facility name not stated
Washington D.C., District of Columbia, United States
Facility name not stated
Jacksonville, Florida, United States
Facility name not stated
Atlanta, Georgia, United States
Facility name not stated
Marietta, Georgia, United States
Facility name not stated
Chicago, Illinois, United States
Facility name not stated
Des Moines, Iowa, United States
Facility name not stated
Kansas City, Kansas, United States
Facility name not stated
Monroe, Louisiana, United States
Facility name not stated
New Orleans, Louisiana, United States
Facility name not stated
Ann Arbor, Michigan, United States
Facility name not stated
Troy, Michigan, United States
Facility name not stated
New York, New York, United States
Facility name not stated
Plainview, New York, United States
Facility name not stated
Syracuse, New York, United States
Facility name not stated
Asheville, North Carolina, United States
Facility name not stated
Durham, North Carolina, United States
Facility name not stated
Raleigh, North Carolina, United States
Facility name not stated
Clevleand, Ohio, United States
Facility name not stated
Providence, Rhode Island, United States
Facility name not stated
Dallas, Texas, United States
Facility name not stated
Galveston, Texas, United States
Facility name not stated
Irving, Texas, United States
Facility name not stated
Charlottesville, Virginia, United States
Facility name not stated
Falls Church, Virginia, United States
Facility name not stated
Richmond, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

GS-9450GS-9450 Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2008
Primary completion: 31 Aug 2009
Completion: 30 Sept 2009
Last update posted: 4 Feb 2014
Registered enrollment: 124
Registry id: NCT00740610

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.